Ruwayda Dham

573 total citations
32 papers, 433 citations indexed

About

Ruwayda Dham is a scholar working on Pharmacology, Pediatrics, Perinatology and Child Health and Pharmacology. According to data from OpenAlex, Ruwayda Dham has authored 32 papers receiving a total of 433 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pharmacology, 10 papers in Pediatrics, Perinatology and Child Health and 8 papers in Pharmacology. Recurrent topics in Ruwayda Dham's work include Pharmacogenetics and Drug Metabolism (8 papers), Pharmaceutical studies and practices (8 papers) and Wound Healing and Treatments (7 papers). Ruwayda Dham is often cited by papers focused on Pharmacogenetics and Drug Metabolism (8 papers), Pharmaceutical studies and practices (8 papers) and Wound Healing and Treatments (7 papers). Ruwayda Dham collaborates with scholars based in Lebanon, Saudi Arabia and United Arab Emirates. Ruwayda Dham's co-authors include Bishara S. Atiyeh, Kusai A. El-Musa, Isra Dmour, Naji M. Najib, Nasir Idkaidek, Qamar uz Zaman, J. Ioannovich, Mohamed F. Yassin, Ahmed Samir and Isam I. Salem and has published in prestigious journals such as SHILAP Revista de lepidopterología, European Journal of Pharmaceutics and Biopharmaceutics and Dermatologic Surgery.

In The Last Decade

Ruwayda Dham

31 papers receiving 415 citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Ruwayda Dham 123 101 95 79 77 32 433
Gerard F. Cooney 9 0.1× 156 1.5× 186 2.0× 67 0.8× 8 0.1× 33 689
Wesley J. Alexander 14 0.1× 69 0.7× 131 1.4× 41 0.5× 5 0.1× 10 481
Michel Lavit 6 0.0× 186 1.8× 36 0.4× 133 1.7× 8 0.1× 36 643
Manish Barvaliya 7 0.1× 236 2.3× 19 0.2× 53 0.7× 92 1.2× 48 588
Hidefumi Kasai 22 0.2× 145 1.4× 15 0.2× 56 0.7× 4 0.1× 37 350
Richard Makins 8 0.1× 25 0.2× 177 1.9× 138 1.7× 18 0.2× 21 565
Horng-Rong Chang 30 0.2× 26 0.3× 42 0.4× 85 1.1× 6 0.1× 18 442
Ajeet Singh 6 0.0× 21 0.2× 71 0.7× 72 0.9× 21 0.3× 90 480
Howard B. Lassman 4 0.0× 149 1.5× 43 0.5× 67 0.8× 6 0.1× 28 466
Emmett Tsz Yeung Wong 7 0.1× 17 0.2× 50 0.5× 51 0.6× 7 0.1× 23 374

Countries citing papers authored by Ruwayda Dham

Since Specialization
Citations

This map shows the geographic impact of Ruwayda Dham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ruwayda Dham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ruwayda Dham more than expected).

Fields of papers citing papers by Ruwayda Dham

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ruwayda Dham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ruwayda Dham. The network helps show where Ruwayda Dham may publish in the future.

Co-authorship network of co-authors of Ruwayda Dham

This figure shows the co-authorship network connecting the top 25 collaborators of Ruwayda Dham. A scholar is included among the top collaborators of Ruwayda Dham based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ruwayda Dham. Ruwayda Dham is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
arani, et al.. (2008). Establishing Therapeutic Bioequivalence of a Generic Salbutamol (Butalin) Metered Dose Inhaler to Ventolin. Biomedical Research-tokyo. 19(1). 0. 1 indexed citations
2.
3.
Dham, Ruwayda, et al.. (2006). Importance of Helicobacter pylori eradcation for maintenance of remission of drug associated peptic ulcer disease. Saudi Journal of Gastroenterology. 12(1). 16–16.
4.
Salem, Isam I., et al.. (2005). Bioequivalence evaluation of two brands of lisinopril tablets (Lisotec and Zestril) in healthy human volunteers. Biopharmaceutics & Drug Disposition. 26(8). 335–339. 10 indexed citations
5.
Salem, Isam I., et al.. (2005). Comparative pharmacokinetics of two tablet formulations of Losartan: bioequivalence assessment. Biopharmaceutics & Drug Disposition. 26(5). 205–210. 20 indexed citations
6.
Najib, Naji M., et al.. (2005). Bioequivalence evaluation of two brands of fluoxetine 20 mg capsules (Flutin and Prozac) in healthy human volunteers. Biopharmaceutics & Drug Disposition. 26(6). 243–247. 1 indexed citations
7.
Atiyeh, Bishara S., et al.. (2004). Moist Exposed Therapy: An Effective and Valid Alternative to Occlusive Dressings for Postlaser Resurfacing Wound Care. Dermatologic Surgery. 30(1). 18–25. 13 indexed citations
8.
Najib, Naji M., et al.. (2004). Bioequivalence assessment of Lovrak (Julphar, UAE) compared with Zovirax (Glaxo Wellcome, UK)‐Two brands of Acyclovir‐in healthy human volunteers. Biopharmaceutics & Drug Disposition. 26(1). 7–12. 8 indexed citations
9.
Najib, Naji M., et al.. (2004). Comparative bioavailability of two brands of atenolol 100 mg tablets (Tensotin and Tenormin) in healthy human volunteers. Biopharmaceutics & Drug Disposition. 26(1). 1–5. 6 indexed citations
10.
Wakeel, Jamal Al, et al.. (2004). The new rHuEPO alpha (epotin) in the management of anemia of end-stage renal disease in patients on mantainence hemodialysis. Transplantation Proceedings. 36(6). 1805–1811. 2 indexed citations
11.
Najib, Naji M., et al.. (2004). Bioequivalence evaluation of two brands of aceclofenac 100mg tablets (Aceclofar and Bristaflam) in healthy human volunteers. Biopharmaceutics & Drug Disposition. 25(3). 103–108. 14 indexed citations
12.
Najib, Naji M., et al.. (2003). Bioequivalence evaluation of two brands of furosemide 40mg tablets (Salurin and Lasix) in healthy human volunteers. Biopharmaceutics & Drug Disposition. 24(6). 245–249. 8 indexed citations
13.
Najib, Naji M., et al.. (2003). Pharmacokinetics and bioequivalence evaluation of two simvastatin 40 mg tablets (Simvast & Zocor) in healthy human volunteers. Biopharmaceutics & Drug Disposition. 24(5). 183–189. 36 indexed citations
14.
Najib, Naji M., et al.. (2003). Bioequivalence evaluation of two brands of enalapril 20mg tablets (narapril and renitec) in healthy human volunteers. Biopharmaceutics & Drug Disposition. 24(7). 315–320. 17 indexed citations
15.
Najib, Naji M., et al.. (2002). Bioequivalence evaluation of two brands of metformin 500 mg tablets (Dialon® & Glucophage®) – in healthy human volunteers. Biopharmaceutics & Drug Disposition. 23(7). 301–306. 23 indexed citations
16.
Atiyeh, Bishara S., et al.. (2002). Benefit–cost analysis of moist exposed burn ointment. Burns. 28(7). 659–663. 40 indexed citations
17.
Najib, Naji M., et al.. (2002). Bioequivalence evaluation of two brands of gliclazide 80 mg tablets (Glyzide® & Diamicron®) — in healthy human volunteers. Biopharmaceutics & Drug Disposition. 23(5). 197–202. 16 indexed citations
18.
Dham, Ruwayda, et al.. (2002). Bioequivalence of Two Brands of Ciprofloxacin 750 Mg Tablets (Sarf® and Ciprobay®) in Healthy Human Volunteers. Drug Development and Industrial Pharmacy. 28(4). 423–429. 7 indexed citations
19.
Carlson, James D., et al.. (2001). Bioequivalence evaluation of lansoprazole 30-mg capsules (Lanfast® and Lanzor®) in healthy volunteers. European Journal of Pharmaceutics and Biopharmaceutics. 51(2). 153–157. 16 indexed citations
20.
Al‐Rashood, Khalid A., et al.. (2000). Bioequivalence evaluation of norfloxacin 400 mg tablets (Uroxin� and Noroxin�) in healthy human volunteers. Biopharmaceutics & Drug Disposition. 21(5). 175–179. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gerard F. Cooney Breakdown of academic impact, for papers by Wesley J. Alexander Breakdown of academic impact, for papers by Michel Lavit Breakdown of academic impact, for papers by Manish Barvaliya Breakdown of academic impact, for papers by Hidefumi Kasai Breakdown of academic impact, for papers by Richard Makins Breakdown of academic impact, for papers by Horng-Rong Chang Breakdown of academic impact, for papers by Ajeet Singh Breakdown of academic impact, for papers by Howard B. Lassman Breakdown of academic impact, for papers by Emmett Tsz Yeung Wong
Rankless by CCL
2026